Joselle Cook, MBBS, Mayo Clinic

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Closing thoughts on unmet needs in the multiple myeloma space, particularly disparities in the care of patients with MM of racial and ethnic minorities.

Dr. Cook and Dr. Pianko share their perspectives on optimizing treatment strategies for individual patients in order to maximize response and mitigate adverse events.

Clinical pearls for community oncologists concerning the real-world application of existing treatments while considering feasibility, cost, and ease of care.

Conversation centered around patient frailty, Dr. Cook and Dr. Pianko emphasize the importance of accurately assessing frailty and adjusting treatment plans accordingly.

Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.

Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.

A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.

A summary of updates from the MAIA and SWOG S0777 studies, with a focus on efficacy and tolerability data.

Joselle Cook, M.B.B.S and Matthew James Pianko, MD discuss available treatment options and goals of therapy for patients with transplant-ineligible NDMM.

Comprehensive insights from experts in Mayo Clinic on the selection and sequencing of CAR T cell therapy or bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Before closing out the panel’s review of clinical data behind bispecifics in relapsed/refractory multiple myeloma, Morie Gertz, MD, highlights use of cevostamab therapy in this setting.

Shared insight from Rafael Fonseca, MD, on data from MonumenTAL-1 and the use of talquetamab therapy in patients with relapsed/refractory multiple myeloma.

Expert perspectives from Joselle Cook, MBBS, on use of elranatamab in relapsed/refractory multiple myeloma based on data from the MagnetisMM-1 trial.

Expert Shaji Kumar, MD, spearheads a review of data from MajesTEC-1 and use of teclistamab therapy in patients with relapsed/refractory multiple myeloma.

Opening the panel’s discussion on multiple myeloma management, Rafael Fonseca, MD, reviews treatment options available to patients at early or late relapse.